Abstract
Colorectal cancer (CRC) is one of the most prevalent cancers, with over one million new cases. The prognosis of CRC considerably depends on the disease stage and metastatic status. As precision oncology for patients with CRC continues to improve, this study aims to integrate genomic, transcriptomic, and proteomic analyses to identify significant expression differences during colorectal progression using a unique set of paired patient samples concerning tumor heterogeneity.
We analyzed fresh-frozen tissue samples of matched healthy colon mucosa, colorectal carcinoma, and liver metastasis from same patients prepared under strict cryogenic conditions. While somatic mutations of known cancer-related genes were analyzed using Illumina’s TruSeq Amplicon Cancer Panel, the transcriptome was assessed comprehensively using Clariom D microarrays. The global proteome was evaluated by liquid chromatography-coupled mass spectrometry (LC-MS/MS) and validated by two-dimensional difference in-gel electrophoresis. Subsequent unsupervised principal component clustering, statistical comparisons, and gene set enrichment analyses were calculated using differential expression results.
While panomics revealed low RNA and protein expression of CA1, CLCA1, MATN2, AHCYL2, and FCGBP in malignant tissues compared to healthy colon mucosa, no differentially expressed RNA or protein targets were detected between tumor and metastatic tissues. Subsequent intra-patient comparisons revealed highly specific expression differences (e.g., SRSF3, OLFM4, and CEACAM5) associated with a patient-individual transcriptome and proteome.
In conclusion, the results highlight the importance of inter- and intra-tumor heterogeneity alongside the individual, patient-paired evaluation for clinical studies. Next to changes among groups reflecting colorectal cancer progression, we identified significant expression differences between patient-individual normal colon mucosa, primary tumor, and liver metastasis, which could speed up the implementation of precision oncology in the future.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by the Ad Infinitum Foundation and the Werner & Clara Kreitz Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of the University of Luebeck gave ethical approval for this work (No. 07-124 and 16-282).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of Interest All authors declare that they have no competing financial interest.
Funding Thorben Sauer received a scholarship from the Ad Infinitum Foundation.
Data Availability
All data are available online at Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/) with the accession number GSE206800 and at ProteomeXchange with the data set identifier PXD036434.
Abbreviations
- 2D-DIGE
- Two-dimensional gel electrophoresis
- CEA/CEACAM5
- Carcinoembryonic antigen
- CLCA1
- calcium-activated chloride channel regulator 1
- CRC
- Colorectal Cancer
- EMT
- epithelial-mesenchymal transition
- FASP
- Filter-aided sample preparation
- GEO
- Gene Expression Omnibus
- H&E
- Hematoxylin and eosin
- HCD
- High-energy collisional dissociation
- LC-MS/MS
- liquid chromatography-coupled mass spectrometry
- LM
- Liver metastases
- mCRC
- metastatic CRC
- NGS
- Next-generation sequencing
- NM
- Normal adjacent colon mucosa
- OLFM4
- Olfactomedin 4
- RTA
- Real-time analysis
- SRSF3
- Serine and arginine-rich splicing factor 3
- T
- Primary colorectal carcinomas
- TCGA
- The Cancer Genome Atlas
- TNC
- Tenascin C
- tNGS
- Targeted amplicon sequencing
- TSACP
- TruSeq™ Amplicon Cancer Panel